Immunome, Inc.
NASDAQ:IMNMBiotechnology
-$0.42 today
- Market cap
- $1.98B
- Beta
- 2.07
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$1.99
Volume 1.41M
Average 1.23M
IMNM Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Immunome, Inc.NASDAQ: IMNM
Selling, General & Admin · Q3 FY2026 · quarter ended Sep 2026
Selling, general & admin growth accelerates
Q3 FY2026 selling, general & admin of $20.86M rose 90.6% year over year, ahead of the +52.3% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 14.3% from the prior quarter. Over 3 fiscal years it compounded at +47.5% a year.
Context
- Selling, general & admin amounted to 630.6% of revenue in FY2025, up 266.1 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 7 analysts of $381.52K (-99.1%) for the fiscal year ending Dec 2026, a slowdown from the +32.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $20.86M+14.3% QoQ
- Last fiscal yearDec 2025
- $43.77M+32.8% YoY
- LTMSep 2026
- $64.15M+52.3% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 43.77M USD
- Year-over-year change
- +32.8%
- 4-year CAGR
- +40.9%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 43.77M | +32.8% |
| FY2024 | 2024-12-31 | 32.96M | +67.7% |
| FY2023 | 2023-12-31 | 19.66M | +44.2% |
| FY2022 | 2022-12-31 | 13.63M | +22.9% |
| FY2021 | 2021-12-31 | 11.09M | — |
Selling, General & Admin vs competitors
How IMNM compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +52.3% is the 2nd highest of 11, against a peer median of +18.0%.
- Over three fiscal years its annual growth of +47.5% compares with a peer median of +12.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $151.41M USD | -3.4% | — | 39.2% | |
| LTM Mar 2026 | $76.67M USD | +0.6% | +17.4% | 120.8% | |
| LTM Sep 2026 | $64.15M USD | +52.3% | +47.5% | — | |
| LTM Mar 2026 | €53.63M EUR | +14.4% | +12.3% | 143.8% | |
| LTM Sep 2026 | $51.3M USD | +21.7% | +17.2% | 45802.7% | |
| LTM Mar 2026 | $38.15M USD | -27.9% | -12.7% | 24.3% | |
| LTM Mar 2026 | $35.33M USD | -27.9% | -11.7% | 35.5% | |
| LTM Mar 2026 | $27.19M USD | +59.1% | +55.2% | — | |
| LTM Sep 2026 | $16.29M USD | +45.3% | -0.9% | — | |
| LTM Mar 2026 | $15.81M USD | +34.6% | +50.4% | — | |
| LTM Mar 2026 | $10.49M USD | +24.0% | +4.5% | — | |
| Peer median (excluding IMNM) | — | +18.0% | +12.3% | 80.0% | |
Competitors are the stored peer set for IMNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 14.02M | 9.04M | 6.94M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 2.96M |
| Gross Profit | 0 | 0 | 14.02M | 9.04M | 3.99M |
| Gross Margin | — | — | 100.0% | 100.0% | 57.4% |
| Research & Development | 14.11M | 23.27M | 23.09M | 129.54M | 174.33M |
| Selling, General & Admin | 11.09M | 13.63M | 19.66M | 32.96M | 43.77M |
| Operating Expenses | 25.2M | 36.9M | 123.55M | 314.84M | 218.1M |
| Depreciation & Amortization | 755K | 631K | 728K | 2.1M | 2.96M |
| EBITDA | (23.95M) | (36.26M) | (28M) | (151.35M) | (209.44M) |
| EBITDA Margin | — | — | -199.7% | -1674.1% | -3017.4% |
| Operating Income | (25.2M) | (36.9M) | (109.53M) | (305.8M) | (214.11M) |
| Operating Margin | — | — | -781.4% | -3382.4% | -3084.8% |
| Interest Income | 10K | 5K | 2.72M | 12.84M | 11.72M |
| Interest Expense | 10K | 5K | 0 | 0 | 0 |
| Other Income / Expenses | 493K | 5K | 2.72M | 12.84M | 1.72M |
| Income Before Tax | (24.71M) | (36.9M) | (106.81M) | (292.96M) | (212.39M) |
| Pre-Tax Margin | — | — | -761.9% | -3240.4% | -3060.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (24.71M) | (36.9M) | (106.81M) | (292.96M) | (212.39M) |
| Net Margin | — | — | -761.9% | -3240.4% | -3060.0% |
| EPS (Basic) | (2.14) | (3.09) | (5.38) | (5.00) | (2.43) |
| EPS (Diluted) | (2.14) | (3.09) | (5.38) | (5.00) | (2.43) |
| Weighted Avg Shares | 11.54M | 12.13M | 19.84M | 58.64M | 87.35M |
| Weighted Avg Shares (Diluted) | 11.54M | 12.13M | 19.84M | 58.64M | 87.35M |
Immunome, Inc.
NASDAQ:IMNM
Intrinsic Alpha fair value
Locked
Current Price
$16.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.